Robert Pietrusko, Pharm.D., serves as Chief Regulatory Officer and Executive Committee member at DBV Technologies. He has directed the global approval of more than 35 new products in multiple therapeutic areas. He recently led the Regulatory Affairs and Quality Assurance group at Vor Bio. As an early team member at Voyager Therapeutics, he pioneered regulatory strategies to transition AAV gene therapies from research into the clinic. Prior to that, he was Vice President of Global Regulatory Affairs & Quality and an Executive Officer at ViroPharma, Inc. He also served as Senior Vice President of Regulatory Affairs at Millennium Pharmaceuticals (now Takeda), spearheading the accelerated approval of Velcade® in the U.S. and in more than 90 countries worldwide. Earlier in his career, Dr. Pietrusko was Vice President of Regulatory Affairs at SmithKline Beecham (now GSK). He has played a key role in pioneering the concept of the Regenerative Medicine Advanced Therapy (RMAT) designation process and served as Chair of the U.S. Intelligence and Regulatory Affairs Advisory Group of the Alliance for Regenerative Medicine (ARM) and was an appointed member of the Regulatory Affairs Committee of the American Society of Gene and Cell Therapies (ASGCT). Dr. Pietrusko holds a B.S. and a Bachelor of Pharmacy from Rutgers University, and a Doctor of Pharmacy degree from the Philadelphia College of Pharmacy and Science. Dr. Pietrusko completed his residency training in hospital pharmacy at Thomas Jefferson University Hospital and is the author or co-author of over 50 publications.